NCT06019468 is a Phase 2 clinical trial of Envolizumab combined with radiotherapy in Thymic Carcinoma, sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

Who is sponsoring NCT06019468?

NCT06019468 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

What drugs are being tested in NCT06019468?

Interventions in NCT06019468: Envolizumab combined with radiotherapy.

What condition does NCT06019468 study?

NCT06019468 studies Thymic Carcinoma.

Is NCT06019468 still recruiting?

NCT06019468 is currently status unknown. Last updated 6 September 2023.

Last reviewed 2023-09-06 · How we verify

NCT06019468

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Treatment For Locally Advanced Thymic Cancer

Status unknown Phase 2 Last updated 6 September 2023

What this trial tests

Phase 2 trial testing Envolizumab combined with radiotherapy in Thymic Carcinoma in 25 participants. Status unknown.

Timeline

4 September 2023

Primary endpoint
30 August 2025

30 December 2025

Quick facts

Lead sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	4 September 2023
Primary completion	30 August 2025
Estimated completion	30 December 2025
Sites	1 location across China

Drugs / interventions tested

Envolizumab combined with radiotherapy

Conditions studied

Thymic Carcinoma — all drugs for Thymic Carcinoma →

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Who can join

Adults 18 to 75, any sex, with Thymic Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aims of this study are to verify the feasibility, effectiveness, and safety of the combination of enrolizumab and radiotherapy for neoadjuvant treatment for locally advanced thymic carcinoma, and to provide recommendations for the establishment of unified evaluation criteria for the neoadjuvant therapy of thymic cancer by evaluating the pathological remission status of thymic cancer specimens after neoadjuvant treatment.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Thymic Epithelial Tumor and Immune System: The Role of Immunotherapy.
Perrino M, Cordua N, De Vincenzo F, Borea F, et al · · 2023 · cited 7× · PMID 38067278 · DOI 10.3390/cancers15235574
A Re-Examination of Neoadjuvant Therapy for Thymic Tumors: A Long and Winding Road.
Yu F, Gu Z, Zhang X, Xu N, et al · · 2024 · cited 4× · PMID 38730630 · DOI 10.3390/cancers16091680
Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy.
Canaslan K, Moeini Nia F, Baez M, Abolhassani H, et al · · 2026 · PMID 41843177 · DOI 10.1007/s00262-026-04311-4

Verify or expand the search:

Other recruiting trials for Thymic Carcinoma

Currently open trials in the same condition.

NCT07181720 — CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT06402708 — Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3) · Phase 3 · recruiting
NCT06301945 — Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors · recruiting
NCT03463460 — Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer · Phase 2 · active not recruiting
NCT03076554 — A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma · Phase 2 · active not recruiting

Other Shanghai Pulmonary Hospital, Shanghai, China trials

Trials by the same sponsor.

NCT07469488 — A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-M · Phase 4 · not yet recruiting
NCT07494591 — TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery · NA · not yet recruiting
NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
NCT07393438 — Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) · Phase 2 · not yet recruiting
NCT07375979 — A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-cente · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06019468 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Pulmonary Hospital, Shanghai, China
Last refreshed: 6 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06019468.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing